Trials / Completed
CompletedNCT01161602
A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Pumosetrag in Patients With Gastroesophageal Reflux Disease (GERD)
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Multiple Dose Levels of Pumosetrag in Patients With Symptoms Associated With Gastroesophageal Reflux Disease (GERD) Receiving a Standard Refluxogenic Meal
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Edusa Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if pumosetrag is effective in treating Gastroesophageal Reflux Disease (GERD) symptoms in patients who have a history of GERD symptoms and are currently taking an acid suppression therapy, such as a Proton Pump Inhibitor (PPI).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pumosetrag | |
| DRUG | Pumosetrag | |
| OTHER | Placebo | |
| DRUG | Pumosetrag |
Timeline
- Completion
- 2011-05-01
- First posted
- 2010-07-13
- Last updated
- 2011-09-21
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01161602. Inclusion in this directory is not an endorsement.